J. Cassidy

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

R. Salazar, J. Cassidy, S. Green, 2014, Cancer Chemotherapy and Pharmacology.

10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial

J. Tabernero, Y. Humblet, D. Cunningham, 2009 .

A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.

D. Kerr, S. Kaye, D. Jodrell, 1994, European journal of cancer.

Guidelines for adjuvant therapy in colorectal cancer. Are they useful? And to whom?

J. Cassidy, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

R. Brown, J. Cassidy, J. Paul, 2009, British Journal of Cancer.

A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.

J. Cassidy, A. Macleod, L. Macdonald, 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

D. Cruickshank, S. M. Crawford, S. Kaye, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.

D. Kerr, K. Mcgregor, S. Kaye, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).

R. Plummer, J. Graham, B. Wiedenmann, 2008, European journal of cancer.

The candidate oncogene ZNF217 is frequently amplified in colon cancer

H. McLeod, S. Curran, J. Cassidy, 2004, The Journal of pathology.

Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.

H. McLeod, J. McKay, S. Curran, 2002, Human pathology.

Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors.

R. Plummer, J. Graham, B. Wiedenmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

B. Reigner, C. Twelves, J. Cassidy, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies

P. Catalano, A. Benson, J. Cassidy, 2007 .

Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data

J. Tabernero, Y. Humblet, D. Cunningham, 2008 .

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

Intergroup collaboration in ovarian cancer: a giant step forward

M. Piccart, M. Parmar, E. Eisenhauer, 1999 .

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

H. McLeod, S. Marsh, J. McKay, 2001, International journal of oncology.

Pharmacokinetics of high molecular weight agents.

S. Wedge, D. Newell, J. Cummings, 1993, Cancer surveys.

Oral fluoropyrimidines in the treatment of colorectal cancer.

H. McLeod, D. Bissett, F. Ahmed, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin

S. Kaye, J. Cassidy, D. Parkin, 1997, Cancer Chemotherapy and Pharmacology.

Impact of deprivation and rural residence on treatment of colorectal and lung cancer

J. Little, J. Cassidy, L. Sharp, 2002, British Journal of Cancer.

Systematic review of cancer treatment programmes in remote and rural areas

J. Little, J. Cassidy, N. Campbell, 1999, British Journal of Cancer.

SCOT: Short Course Oncology Therapy-A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer.

A. Briggs, J. Cassidy, A. Haydon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.

S. J. Johnston, H. McLeod, F. Ahmed, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential of Xeloda® in Colorectal Cancer and Other Solid Tumors

J. Cassidy, 1999, Oncology.

Autoregulation of 5-fluorouracil metabolism.

J. Sludden, H. McLeod, J. Cassidy, 1998, European journal of cancer.

Liver metastases from breast cancer: management of patients with significant liver dysfunction.

J. Cassidy, P. Canney, M. Mano, 2005, Cancer treatment reviews.

Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

K. Sikora, D. Cunningham, S. Kaye, 1991, The Lancet.

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

L. Murray, P. Vasey, C. Twelves, 1999, British Journal of Cancer.

The place of polymer prodrugs in cancer therapy

J. Cassidy, F. Coxon, J. Cassidy, 2000 .

1LB 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage-III colon cancer

W. Scheithauer, C. Twelves, J. Cassidy, 2007 .

Cerivastatin enhances the cytotoxicity of 5‐fluorouracil on chemosensitive and resistant colorectal cancer cell lines

J. Cassidy, Weiguang Wang, E. Collie-Duguid, 2002, FEBS letters.

Characterization of the topoisomerase I locus in human colorectal cancer.

H. McLeod, S. Marsh, J. Cassidy, 2000, Cancer genetics and cytogenetics.

c-erbB-2 is not a major factor in the development of colorectal cancer

H. McLeod, J. McKay, V. Ross, 2002, British Journal of Cancer.

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?

A. Briggs, J. Cassidy, Gaynor J. Bates, 2011, Trials.

15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

J. Cassidy, T. Maughan, D. Fisher, 2009 .

Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS).

J. Tabernero, Y. Humblet, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy

J. Tabernero, Y. Humblet, D. Cunningham, 2011 .

Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study)

D. Cunningham, J. Bridgewater, P. Mainwaring, 2005 .

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Daniel J Sargent, Greg Yothers, Qian Shi, 2013, Clinical colorectal cancer.

Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil

G. Zachos, R. Brown, D. Gillespie, 2006, Oncogene.

Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?

J. Cassidy, 2007, Nature Clinical Practice Oncology.

Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.

J. Cassidy, 2005, Clinical colorectal cancer.

A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 {+/-} bevacizumab (A)

W. Scheithauer, S. Clarke, A. Figer, 2007 .

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

T. Conroy, J. Tabernero, A. Figer, 2001 .

Comparison of 5‐Fluorouracil Pharmacokinetics in Whole Blood, Plasma, and Red Blood Cells in Patients with Colorectal Cancer

H. McLeod, J. Cassidy, J. Cassidy, 1997, Pharmacotherapy.

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

D. Cruickshank, S. M. Crawford, S. Kaye, 1992, The Lancet.

The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction.

L. Murray, D. Kerr, S. Kaye, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cell cycle perturbation and acquired 5-fluorouracil chemoresistance.

V. O’Brien, J. Cassidy, Weiguang Wang, 2008, Anticancer research.

Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks

H. McLeod, J. Cassidy, Weiguang Wang, 2007, Cancer Chemotherapy and Pharmacology.

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial.

W. Scheithauer, C. Twelves, J. Cassidy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.

B. Reigner, D. Bissett, L. Dirix, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer

L. Saltz, J. Cassidy, J. Fuloria, 2007 .

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

L. Murray, S. Kaye, D. Jodrell, 1994, British Journal of Cancer.

Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

D. Kerr, D. Bissett, P. Meredith, 1991, British journal of cancer.

cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.

R. Makuch, D. V. Von Hoff, J. Cassidy, 1979, Cancer treatment reports.

Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study

J. Cassidy, T. Iveson, A. Harkin, 2011, Trials.

The changing role of surgery in metastatic non-seminomatous germ cell tumour.

S. Kaye, J. Cassidy, C. Lewis, 1992, British Journal of Cancer.

Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer

D. Kerr, S. Kaye, J. Cassidy, 2008, Cancer Chemotherapy and Pharmacology.

Intergroup collaboration in ovarian cancer: a giant step forward.

M. Piccart, M. Parmar, E. Eisenhauer, 1999, Annals of Oncology.

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

R. Salazar, D. Bissett, S. Ritland, 2004, Clinical Cancer Research.

Efficacy, safety, and cost of new anticancer drugs

A. Harris, D. Jodrell, J. Cassidy, 2002, BMJ : British Medical Journal.

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

H. McLeod, D. Bissett, M. Collier, 2001, British Journal of Cancer.

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

H. McLeod, D. Bissett, M. Collier, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.

P. Vasey, S. Kaye, A. Calvert, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

W. Rapeport, S. Kaye, J. Cassidy, 1988, British Journal of Cancer.

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

B. Reigner, D. Jodrell, J. Cassidy, 1999, Cancer Chemotherapy and Pharmacology.

Tolerability of fluoropyrimidines appears to differ by region.

E. Van Cutsem, D. Haller, L. Saltz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why patient representation might harm science?

J. Cassidy, 2007, Breast Cancer Research.

Edinburgh Research Explorer The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patients

Janeane L. Walker, J. Cassidy, M. Sharpe, 2018 .

Phase I and pharmacokinetic study of flavone acetic acid.

D. Kerr, S. Kaye, J. Cassidy, 1987, Cancer research.

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

D. Bisset, D. Jodrell, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties

Kannappan, J. Cassidy, P. Liu, 2011, British Journal of Cancer.

Chemotherapy administration: doses, infusions and choice of schedule.

J. Cassidy, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study

J. Sludden, A. Boddy, D. Bisset, 2001 .

Polymer-directed enzyme prodrug therapy.

J. Cassidy, 2000, Drug news & perspectives.

Polymer-drug conjugates for the treatment of cancer

J. Cassidy, R. Duncan, L. German, 1998 .

Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?

H. McLeod, J. Cassidy, E. Collie-Duguid, 2000, Annals of Oncology.

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

B. Reigner, S. Durston, J. Cassidy, 2000, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics, targeting and delivery systems in anthracycline-resistant cancers.

J. Cassidy, 1995, European journal of cancer.

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.

J. Sludden, H. McLeod, J. Cassidy, 1998, British Journal of Cancer.

A phase II study of Tomudex in relapsed epithelial ovarian cancer.

H. Earl, M. Gore, J. Cassidy, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group.

S. Bicknell, J. Cassidy, W. Steward, 1995, European journal of cancer.

Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.

H. McLeod, S. Marsh, J. McKay, 2002, Oncology reports.

The treatment of advanced colorectal cancer with interferon-α: a review

F. Ahmed, J. Cassidy, 1999 .

Tumour-targeted drug and gene delivery: principles and concepts

A. Schätzlein, J. Cassidy, 2004, Expert Reviews in Molecular Medicine.

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.

A. te Velde, J. Verweij, L. Dirix, 1996, European journal of cancer.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)

W. Scheithauer, L. Saltz, S. Clarke, 2007 .

Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines.

Bing-Zhong Xu, J. Cassidy, A. Armesilla, 2010, Cancer letters.

Herpes simplex virus,Candida albicans and mouth ulcers in neutropenic patients with non-haematological malignancy

J. Cassidy, R. Leonard, L. Milne, 2004, Cancer Chemotherapy and Pharmacology.

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

L. Murray, P. Vasey, S. Kaye, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapeutic opportunities from tumour biology in metastatic colon cancer.

H. McLeod, J. McKay, J. Cassidy, 2000, European journal of cancer.

Regulation of dihydropyrimidine dehydrogenase in colorectal cancer.

S. J. Johnston, H. McLeod, J. Cassidy, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

A. Briggs, T. Hickish, J. Tabernero, 2018, The Lancet. Oncology.

Colorectal cancer genomics: evidence for multiple genotypes which influence survival

H. McLeod, S. Marsh, N. Haites, 2001, British Journal of Cancer.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

T. Hickish, J. Cassidy, I. Macpherson, 2014, European journal of cancer.

Comparative genomic hybridization and chromosomal instability in solid tumours

H. McLeod, N. Haites, J. Cassidy, 1999, British Journal of Cancer.

Chemotherapy in metastatic colorectal cancer.

J. Cassidy, C. Kelly, 2007, Surgical oncology.

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.

M. Piccart, E. Eisenhauer, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in Combinational Oncology Studies

J. Cassidy, I. Macpherson, 2008, Pharmaceutical Medicine.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

M. Piccart, K. Swenerton, B. Zee, 2000, Journal of the National Cancer Institute.

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

J. Cassidy, Robert J. Jones, E. Díaz-Rubio, 2007, Clinical Cancer Research.

Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas

P. Donnan, A. Munro, J. Cassidy, 2004, British Journal of Cancer.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

S. Marsh, J. Cassidy, H. Mcleod, 2001, Cancer research.

Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors.

P. Johnston, H. McLeod, S. Marsh, 1998, Cancer research.

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

K. Simonsen, P. Fracasso, J. Cassidy, 2018, European Journal of Cancer.

Emerging drugs in colorectal cancer

J. Cassidy, L. Scott, J. Fraser, 2003, Expert opinion on emerging drugs.

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

L. Paz-Ares, P. O'dwyer, S. Kaye, 1998, British Journal of Cancer.

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial

D. Haller, M. Saif, H. Schmoll, 2014, British Journal of Cancer.

Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors

C. Twelves, J. Cassidy, P. Schöffski, 2005, Clinical Cancer Research.

In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines

J. Cassidy, A. Schatzlein, A. Armesilla, 2007, British Journal of Cancer.

New oxaliplatin‐based combinations in the treatment of colorectal cancer

J. Cassidy, H. Hochster, 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Pharmacological Advances in Metastatic Colorectal Cancer Management

J. Cassidy, 2011 .

Phase I and pharmacokinetic study of rhizoxin.

D. Bissett, S. Kaye, J. Cassidy, 1992, Cancer research.

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

J. Sludden, A. Boddy, D. Bissett, 2005, Clinical Cancer Research.

Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines

H. McLeod, J. Cassidy, Weiguang Wang, 2003, International journal of cancer.

Capecitabine in the treatment of colorectal cancer

J. Cassidy, C. Kelly, 2007, Expert review of anticancer therapy.

Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?

C. Twelves, J. Cassidy, CJ Twelves, 2002, British Journal of Cancer.

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

H. Burger, J. Verweij, E. Van Cutsem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase

John D. Roberts, H. McLeod, D. Bissett, 2000 .

Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG 2034 1

John D. Roberts, H. McLeod, D. Bissett, 2000 .

Adjuvant therapy in colon cancer

J. Graham, J. Cassidy, 2012, Expert review of anticancer therapy.

Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer.

N. Douglas, C. Espie, J. Cassidy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells

Kevin M. Ryan, K. Ryan, V. O’Brien, 2004, Cancer Research.

Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells

J. Cassidy, W. Wang, 2003, British Journal of Cancer.

Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case–control study in a population with relatively low folate intake

J. Little, N. Haites, J. Cassidy, 2008, British Journal of Nutrition.

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

E. Van Cutsem, N. Harbeck, D. Miles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.

D. Kerr, T. Powles, G. Rustin, 1992, Oncology.

Thymidylate synthase inhibitors in colorectal cancer.

J. Cassidy, 2000, Seminars in Oncology.

Non-Ionic Surfactant Vesicles as Carriers of Doxorubicin

S. Kaye, J. Cassidy, A. Florence, 1990 .

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

J. Sludden, H. McLeod, F. Gonzalez, 1998, British Journal of Cancer.

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

E. Van Cutsem, L. Saltz, D. Cunningham, 2009, British Journal of Cancer.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: A case‐control study in the Grampian region of Scotland

J. Little, N. Haites, J. Cassidy, 2006, International journal of cancer.

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

D. Jodrell, J. Cassidy, M. Mackean, 1998, British Journal of Cancer.

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Jassem, J. Canon, J. Douillard, 2010 .

Thoracic malignancies

D. Bissett, J. Cassidy, G. Morris-Stiff, 2018, Oxford Medicine Online.

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

F. Kabbinavar, H. Hurwitz, L. Saltz, 2009, Journal of Cancer Research and Clinical Oncology.

Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) to first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial

J. Cassidy, T. Maughan, D. Fisher, 2010 .

Vitamin D (and its analogs) in the treatment and prevention of cancer

J. Cassidy, H. Glen, 2006, Expert review of anticancer therapy.

Late effects of chemotherapy and radiotherapy

D. Bissett, J. Cassidy, G. Morris-Stiff, 2015, Oxford Medicine Online.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

A. Briggs, T. Hickish, J. Tabernero, 2019, Health technology assessment.

Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer

C. Wilson, C. Boni, A. Figer, 2000 .

Flavone acetic acid: a nonlinear pharmacokinetic model

D. Kerr, S. Kaye, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

W. Scheithauer, L. Saltz, S. Clarke, 2007 .

A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection.

P. Vasey, J. Cassidy, M. Strolin Benedetti, 1995, Journal of pharmaceutical and biomedical analysis.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

J. Cassidy, I. Macpherson, C. Lindsay, 2009, Future oncology.

Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer. The NOCOVA

M. Piccart, S. Kaye, J. Cassidy, 1997 .

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

C. Weitzel, C. Twelves, J. Cassidy, 2001, European journal of cancer.

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

P. Kristjansen, J. Cassidy, E. Ehrnrooth, 2012, British Journal of Cancer.

Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology

S. Kaye, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and Pharmacokinetic Study of Flavone Acetic Acid 1

D. Kerr, S. Kaye, J. Cassidy, 2006 .

Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?

D. Kerr, S. Kaye, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).

D. Kerr, D. Cunningham, S. Kaye, 1986, Cancer research.

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

D. Bissett, C. Twelves, J. Cassidy, 2004, British Journal of Cancer.

A pilot study of subjective well-being in colorectal cancer patients and their caregivers

J. Graham, J. Cassidy, P. Spiliopoulou, 2017, Patient Related Outcome Measures.

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

D. Jodrell, C. Twelves, J. Cassidy, 1998, British Journal of Cancer.

Striking the right balance in colorectal cancer care--a qualitative study of rural and urban patients.

J. Cassidy, N. Campbell, L. Ritchie, 2002, Family practice.

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

R. Simes, A. Broad, V. Ganju, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

REVIEW OF OXALIPLATIN: AN ACTIVE PLATINUM AGENT IN COLORECTAL CANCER

J. Cassidy, 2000, International journal of clinical practice.

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.

B. Reigner, R. Camidge, D. Jodrell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy.

L. Frenz, I. Judson, C. Twelves, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

B. Reigner, K. O'Byrne, D. Cameron, 1999, Cancer Chemotherapy and Pharmacology.

Evaluating the potential of polymer nanoparticles for oral delivery of paclitaxel in drug-resistant cancer

J. Cassidy, J. Plumb, V. Bhardwaj, 2010, Cancer nanotechnology.

Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).

D. Bissett, P. Wilson, P. Vasey, 1995, Cancer research.

Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas.

P. Johnston, H. McLeod, J. McKay, 2000, International journal of oncology.

High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood.

H. McLeod, J. Cassidy, K. Kendle, 1997, Journal of chromatography. B, Biomedical sciences and applications.

A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid

C. Twelves, J. Cassidy, M. Devlin, 2004, Cancer Chemotherapy and Pharmacology.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.

C. Redfern, J. Carmichael, D. Cunningham, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.

J. Zaluski, D. Cunningham, J. Bridgewater, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical study of LL-D49194α1 with retrospective pharmacokinetic investigations in mice and humans

D. Kerr, S. Kaye, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Cancer Management and Research Dovepress Use of Capecitabine in Management of Early Colon Cancer Colon Cancer Prognostic/predictive Markers to Define Adjuvant Treatment of Colon Cancer

J. Cassidy, H. Hameed, 2022 .

Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer

J. Cassidy, J. Plumb, A. Chalmers, 2016, Oncotarget.

Phase I Trials in Oncology: Design and Endpoints

J. Cassidy, H. Glen, 2014 .

Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer.

H. McLeod, K. Kerr, M. Nicolson, 2000, Cancer research.

Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study

P. Rougier, W. Schmiegel, C. Weitzel, 2001 .

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2002 .

Dietary intake of folate and related micronutrients, genetic polymorphisms in MTHFR and colorectal cancer A population-based case-control study in Scotland

J. Little, N. Haites, J. Cassidy, 2002 .

Genetic polymorphisms in folate metabolism, dietary folate intake and colorectal cancer: a population-based case-control study

J. Little, N. Haites, J. Cassidy, 2001 .

Comprar Oxford Handbook of Oncology | Jim Cassidy | 9780199563135 | Oxford University Press

D. Bissett, J. Cassidy, R. Spence, 2010 .

Tumours of the central nervous system

D. Bissett, J. Cassidy, G. Morris-Stiff, 2015 .

The treatment of advanced colorectal cancer with interferon-alpha: a review.

F. Ahmed, J. Cassidy, 1999, Expert opinion on investigational drugs.